XERS insider trading
NasdaqGS HealthcareXeris Biopharma Holdings, Inc.: insider trade history from SEC Form 4 filings.
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Company website: www.xerispharma.com
XERS insider activity at a glance
FilingIQ tracks 324 insider transactions for XERS in filings since Jun 25, 2018. The most recent transaction is dated Oct 1, 2026.
Across the full history, 39 open-market purchases
and 60 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on XERS insider trades is 54.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest XERS Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for XERS?
- FilingIQ tracks 324 Form 4 insider transactions for XERS (Xeris Biopharma Holdings, Inc.), covering filings from Jun 25, 2018 onwards. 12 of those are dated within the last 90 days.
- Are XERS insiders net buyers or net sellers?
- Across the full Form 4 history for XERS, 39 transactions (12%) were open-market purchases and 60 (19%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does XERS insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is XERS in?
- Xeris Biopharma Holdings, Inc. (XERS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.10B.
Methodology & sources
Every XERS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.